Cambridge Investment Research Advisors
LUCD icon

Cambridge Investment Research Advisors’s Lucid Diagnostics LUCD Stock Holding History

Cambridge Investment Research Advisors’s Portfolio LUCD Stock Details LUCD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-10,000
Closed -$15K – 3709
2025
Q1 		$15K Buy
+10,000
New +$12K ﹤0.01% 3469

Other funds holding LUCD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MCM
Masters Capital Management Atlanta, Georgia $3.03B AUM 57.21% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
LM
Luminus Management Houston, Texas $166M AUM 75.95% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Lido Advisors
Lido Advisors Los Angeles, California $32.7B AUM 19.2% 1-Year Est. Return

Cambridge Investment Research Advisors's LUCD Position: Q2 2025 in Review

Cambridge Investment Research Advisors sold out of Lucid Diagnostics (LUCD) in Q2 2025, closing a stake of 10,000 shares — an estimated $15K sold.

Cambridge Investment Research Advisors first reported a position in LUCD in Q1 2025 and held it in 1 quarter. The position peaked at $15K in Q1 2025. 72 funds tracked by Wall St. Rank hold LUCD as of Q2 2025.

  • Cambridge Investment Research Advisors reported no remaining Lucid Diagnostics position as of Q2 2025 after selling out during the quarter.
  • Cambridge Investment Research Advisors sold 10,000 Lucid Diagnostics shares in Q2 2025, an estimated $15K.
  • Cambridge Investment Research Advisors first reported a position in Lucid Diagnostics in Q1 2025 and held it in 1 quarter.
  • Cambridge Investment Research Advisors's Lucid Diagnostics position peaked at $15K in Q1 2025.
  • 72 funds tracked by Wall St. Rank held Lucid Diagnostics as of Q2 2025.

Based on Cambridge Investment Research Advisors's 13F filing for Q2 2025, filed 31 Jul 2025.